Friday, July 7, 2017
FDA Approves Endari for Sickle Cell Disease
It should not come as a surprise to readers of this blog- Emmaus Medical was given FDA approval for it's l-glutamine treatment for sickle cell disease. I posted my analysis of the then-pending application back on June 17th: Good News for Sickle-Cell Patients, But How Will Emmaus Make Money? A Look at the Business Side of Pharmaceutical Policy. As I stated then- it will be very interesting to see whether Emmaus is able to successfully complete with other sources of l-glutamine. I look forward to Emmaus' quarterly reports.